Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$59.18 USD
-1.25 (-2.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $59.17 -0.01 (-0.02%) 7:18 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$59.18 USD
-1.25 (-2.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $59.17 -0.01 (-0.02%) 7:18 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
J&J Seeks Label Expansion of Darzalex Faspro for Amyloidosis
by Zacks Equity Research
J&J (JNJ) files sBLA to the FDA for expanding the label of Darzalex Faspro to treat patients with light chain amyloidosis. Currently, there are no approved therapies for the disease.
Halozyme Therapeutics (HALO) Down 1.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Halozyme (HALO) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Halozyme (HALO) reports lower-than-expected Q2 earnings. Shares down.
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -24.00% and -20.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Q2 Earnings on Aug 10: NVAX, ICPT & More
by Kinjel Shah
Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.
Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roche's SC Formulation of Perjeta-Herceptin Combo Gets FDA Nod
by Zacks Equity Research
Roche (RHHBY) receives FDA approval for a fixed-dose combination of Perjeta and Herceptin, Phesgo, plus chemotherapy as a treatment for HER2-positive breast cancer.
Why Halozyme Therapeutics (HALO) Stock Might be a Great Pick
by Zacks Equity Research
Halozyme Therapeutics (HALO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Why Is Halozyme Therapeutics (HALO) Up 1% Since Last Earnings Report?
by Zacks Equity Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
J&J's Darzalex Subcutaneous Version Gets Approval in Europe
by Zacks Equity Research
J&J (JNJ) announces approval of subcutaneous formulation of Darzalex for all current MM indications in first-line as well as relapsed/refractory multiple myeloma.
ACADIA to Merge Two Phase III Studies on Nuplazid for MDD
by Zacks.com
ACADIA (ACAD) to club two late-stage studies on Nuplazid into a single evaluation program for the adjunctive treatment of MDD. Top-line results from the same are expected in Q3.
argenx Up on Positive Data from Pivotal Efgartigimod Study
by Zacks Equity Research
argenx's (ARGX) lead pipeline candidate, efgartigimod, meets primary endpoint in a pivotal study evaluating it in myasthenia gravis. A BLA is likely to be filed by the end of 2020.
Why Halozyme (HALO) Could Be Positioned for a Surge
by Zacks Equity Research
Halozyme (HALO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Why Halozyme (HALO) Stock Might be a Great Pick
by Zacks Equity Research
Halozyme (HALO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Top Ranked Momentum Stocks to Buy for May 15th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 15th
Halozyme (HALO) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Halozyme (HALO) reports wider-than-expected Q1 loss. Shares down.
Halozyme Therapeutics (HALO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -300.00% and -35.57%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Halozyme Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Halozyme Therapeutics
Analysts Estimate Halozyme Therapeutics (HALO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Halozyme Therapeutics (HALO) Down 20.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Halozyme Therapeutics (HALO) Stock a Solid Choice Right Now?
by Zacks Equity Research
Halozyme Therapeutics (HALO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Trevena's NDA for Pain Drug Oliceridine Gets FDA Acceptance
by Zacks Equity Research
FDA accepts Trevena's (TRVN) NDA for opioid analgesic, oliceridine, re-submitted last month. A decision is expected in August.
Surging Earnings Estimates Signal Good News for Halozyme (HALO)
by Zacks Equity Research
Halozyme (HALO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.